Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mirum Pharmaceuticals, Inc.

42.54
+1.232.98%
Pre-market: 42.16-0.3800-0.89%09:18 EDT
Volume:444.11K
Turnover:18.82M
Market Cap:2.10B
PE:-22.99
High:42.96
Open:41.05
Low:40.29
Close:41.31
Loading ...

Press Release: Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Dow Jones
·
49 mins ago

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?

Zacks
·
25 Apr

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

MT Newswires Live
·
14 Apr

BRIEF-Mirum’S Livmarli Now FDA Approved In Tablet Formulation

Reuters
·
14 Apr

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire
·
14 Apr

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Apr

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
04 Apr

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Zacks
·
03 Apr

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Zacks
·
28 Mar

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

MT Newswires Live
·
27 Mar

BRIEF-LIVMARLI Now Approved In Japan For ALGS And PFIC

Reuters
·
27 Mar

Livmarli NOW Approved in Japan for Algs and Pfic

THOMSON REUTERS
·
27 Mar

LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire
·
27 Mar

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.
·
25 Mar

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Simply Wall St.
·
21 Mar

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
11 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
03 Mar

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Simply Wall St.
·
01 Mar

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb

Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $72 From $66

THOMSON REUTERS
·
28 Feb